POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; it maintains intracellular tonicity, transmits nerve impulses, and contracts muscles. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains extracellular fluid volume and tonicity.
| Metabolism | Potassium is excreted primarily by the kidneys; dextrose is metabolized to carbon dioxide and water; sodium chloride is excreted mainly by the kidneys. |
| Excretion | Renal: >90% of potassium, dextrose (metabolized), and sodium are eliminated renally. Potassium is primarily excreted by the kidneys (90-95%) with a small fraction (5-10%) eliminated in feces. Dextrose is completely metabolized to carbon dioxide and water, with no significant biliary excretion. Sodium is excreted mainly in urine (>95%) with minimal fecal loss. |
| Half-life | Potassium: 7.5 hours (distribution) with terminal half-life dependent on renal function; in normal renal function, effective half-life for potassium homeostasis is ~4-6 hours. Dextrose: Immediate metabolism; not applicable. Sodium: 12-24 hours (renal handling) but varies with sodium balance. |
| Protein binding | Potassium: Not significantly protein-bound (<2%). Dextrose: Not protein-bound. Sodium: Not protein-bound (<5% bound to albumin). |
| Volume of Distribution | Potassium: 0.67 L/kg (total body water); clinical meaning: distributes throughout extracellular and intracellular compartments, but intracellular uptake is slow. Dextrose: 0.2 L/kg (extracellular fluid). Sodium: 0.25 L/kg (extracellular fluid). |
| Bioavailability | Intravenous: 100% for all components. Oral (not applicable for this formulation): N/A. IM/SC: Not recommended due to irritation. |
| Onset of Action | Intravenous: Immediate; potassium effects on membrane potential occur within minutes. Dextrose: Onset of caloric effect within minutes. Sodium: Onset of volume expansion within minutes. |
| Duration of Action | Potassium: Duration of supplementation is 4-6 hours depending on infusion rate and renal function; continuous infusion required for sustained effect. Dextrose: Duration of glucose elevation is short-lived (1-2 hours) due to rapid insulin release. Sodium: Duration depends on volume status; excess sodium is excreted over 12-24 hours. |
Intravenous infusion; rate determined by clinical need; typical adult maintenance: 100-200 mL/hour (equivalent to KCl 0.15 g/hour, dextrose 10 g/hour, sodium chloride 0.2 g/hour) based on fluid and electrolyte requirements; maximum infusion rate: KCl 10 mEq/hour (0.75 g/hour) or 200 mL/hour, whichever is lower; do not exceed 200 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Avoid use due to risk of hyperkalemia and fluid overload; consider alternative therapy. GFR 30-50 mL/min: Use with caution, reduce infusion rate by 50% and monitor serum potassium and renal function closely. GFR >50 mL/min: No adjustment required. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; reduce infusion rate by 25-50% and monitor serum potassium and ammonia levels. Child-Pugh Class C: Avoid use; risk of hyperkalemia and precipitation of hepatic encephalopathy. |
| Pediatric use | Weight-based: Infuse at 0.5-1 mL/kg/hour (equivalent to KCl 0.75-1.5 mg/kg/hour, dextrose 0.5-1 g/kg/hour, sodium chloride 1-2 mg/kg/hour); maximum rate: 2 mL/kg/hour; adjust based on serum electrolytes, glucose, and fluid status. Not recommended for neonates due to high dextrose concentration (10%) unless under strict monitoring. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium, dextrose, and sodium are endogenous substances normally present in breast milk. Exogenous IV administration of these at standard doses is not expected to significantly increase milk concentrations. M/P ratio for potassium is approximately 0.1-0.3; dextrose is negligible; sodium is similar. Use during breastfeeding is considered compatible. However, monitor maternal electrolyte and glucose status. |
| Teratogenic Risk |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted and used only in patients with severe hypokalemia; rapid infusion can cause fatal hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Acute dehydration","Addison's disease","Severe renal failure with oliguria/anuria","Concurrent use of potassium-sparing diuretics or ACE inhibitors (relative)"]
| Precautions | ["Risk of hyperkalemia, especially in patients with renal impairment or those receiving potassium-sparing diuretics","Do not administer unless solution is clear and container undamaged","Use with caution in patients with heart failure, severe renal insufficiency, or conditions predisposing to hyperkalemia","Monitor serum electrolytes, glucose, and fluid balance"] |
Loading safety data…
| Initiate at lower end of dosing range (e.g., 50-100 mL/hour) due to decreased renal function and higher risk of electrolyte imbalances and fluid overload; monitor serum potassium, glucose, and renal function frequently; avoid in patients with heart failure or significant renal impairment (GFR <30 mL/min). |
| First trimester: Potassium chloride at usual replacement doses is not associated with major malformations. Dextrose may be given as needed for maternal hypoglycemia but high doses near delivery may cause neonatal hypoglycemia. Sodium chloride at typical replacement doses is not teratogenic. Second and third trimesters: Potassium chloride is safe; however, avoid hyperkalemia as it may cause maternal cardiac effects. Dextrose infusion may cause maternal hyperglycemia and subsequent fetal hyperinsulinemia leading to neonatal hypoglycemia. Sodium chloride excess can contribute to fluid overload and hypertension. Overall, no directly teratogenic risk from these components at standard therapeutic doses. |
| Fetal Monitoring | Maternal: Serum electrolytes (potassium, sodium), glucose, fluid balance, urine output, cardiac monitoring if rapid infusion; fetal: heart rate monitoring if maternal hyperglycemia occurs; ultrasound for growth if prolonged use. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride, dextrose, or sodium chloride at therapeutic doses. Unlikely to impact reproductive function. |